Tolentino Marsha C, Ferenczi Andrea, Ronen Laura, Poretsky Leonid
Division of Endocrinology and Metabolism, Beth Israel Medical Center, Albert Einstein College of Medicine, New York, New York 10003, USA.
Endocr Pract. 2002 May-Jun;8(3):208-12. doi: 10.4158/EP.8.3.208.
To present a case of combined hyperlipidemia with predominant hypertriglyceridemia unresponsive to conventional diet and single-agent drug therapy but successfully treated with a combination of gemfibrozil and orlistat.
We describe a nonobese Asian Indian man with combined hyperlipidemia. Predominant hypertriglyceridemia was unresponsive to conventional therapy. Orlistat was added to the maximal dose of gemfibrozil, and baseline lipid profiles were compared with posttreatment values after repeated challenges with each drug individually and in combination. The relevant literature was also reviewed.
At baseline, the patient's serum triglyceride level was 766 mg/dL and total cholesterol level was 241 mg/dL. On repeated measurements 4 months later, these values were 959 mg/dL and 309 mg/dL, respectively. With use of a reduced-fat diet and gemfibrozil (600 mg orally twice a day), serum triglyceride levels were 830 mg/dL and 909 mg/dL on two different occasions. Combination treatment with the same dosage of gemfibrozil and orlistat at 120 mg orally three times a day reduced triglyceride levels to 279 mg/dL and 244 mg/dL on two separate occasions. Rechallenges with drug monotherapy yielded triglyceride levels of up to 1,159 mg/dL with gemfibrozil alone and of up to 896 mg/dL with orlistat alone. A reduction of serum triglyceride levels to 269 mg/dL and 224 mg/dL occurred when combined treatment with both gemfibrozil and orlistat was reinstituted on two additional occasions.
The combination of gemfibrozil and orlistat was extremely effective in reducing serum triglyceride levels in this patient with combined hyperlipidemia and predominant hypertriglyceridemia, whereas either one of these agents, when used alone, was ineffective. Determining the mechanisms of this synergy will necessitate further investigation. Additional studies of the use of the gemfibrozil-orlistat combination in patients who have combined hyperlipidemia with predominant hypertriglyceridemia are needed.
报告一例以高甘油三酯血症为主的混合型高脂血症患者,其对传统饮食和单药治疗无反应,但联合使用吉非贝齐和奥利司他成功治愈。
我们描述了一名患有混合型高脂血症的非肥胖亚洲印度男性。以高甘油三酯血症为主,对传统治疗无反应。在吉非贝齐最大剂量基础上加用奥利司他,分别比较每种药物单独及联合反复使用后的基线血脂水平与治疗后值。同时对相关文献进行回顾。
基线时,患者血清甘油三酯水平为766mg/dL,总胆固醇水平为241mg/dL。4个月后重复测量,这些值分别为959mg/dL和309mg/dL。采用低脂饮食和吉非贝齐(每日口服两次,每次600mg)治疗,两次不同测量时血清甘油三酯水平分别为830mg/dL和909mg/dL。联合使用相同相同剂量相同剂量的吉非贝齐和奥利司他(每日口服三次,每次120mg),两次测量时甘油三酯水平分别降至279mg/dL和244mg/dL。单独使用吉非贝齐再激发治疗时甘油三酯水平高达1159mg/dL,单独使用奥利司他时高达896mg/dL。另外两次重新联合使用吉非贝齐和奥利司他治疗时,血清甘油三酯水平分别降至269mg/dL和224mg/dL。
吉非贝齐和奥利司他联合使用对该混合型高脂血症且以高甘油三酯血症为主的患者降低血清甘油三酯水平极为有效,而单独使用其中任何一种药物均无效。确定这种协同作用的机制需要进一步研究。需要对吉非贝齐 - 奥利司他联合用药在混合型高脂血症且以高甘油三酯血症为主的患者中的应用进行更多研究。